Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL28102305 | 0.82 | TSHR (0.78) | TSHRHCAR2CHRM2CHRM4CHRM1 | |
| SCHEMBL19193 | 0.82 | — | — | |
| SCHEMBL21064874 | 0.82 | TSHR (1.00) | TSHRHCAR2CHRM2CHRM4CHRM1 | |
| Formamide SCHEMBL8708733 | 0.80 | TSHR (0.74) | TSHRHCAR2CHRM2CHRM4CHRM1 | |
| SCHEMBL28276475 | 0.79 | TSHR (0.82) | TSHRHCAR2CHRM2CHRM4CHRM1 | |
| Methyl Alcohol SCHEMBL584909 | 0.79 | — | — | |
| Ammonia Solution, Strong SCHEMBL5086843 | 0.79 | — | — | |
| SCHEMBL4431010 | 0.79 | TSHR (0.93) | TSHRHCAR2CHRM2CHRM4CHRM1 | |
| SCHEMBL3495565 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL2107550 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2956439-B1 | PROCESS FOR PREPARING ATAZANAVIR SULPHATE | CIPLA LTD (IN) | 2019-01-09 | — | — | EP | claimed |
| US-9890121-B2 | Process for preparing atazanavir sulphate | CIPLA LIMITED (IN) | 2018-02-13 | — | — | US | claimed |
| US-20160002166-A1 | Process for Preparing Atazanavir Sulphate | CIPLA LIMITED (IN) | 2016-01-07 | — | — | US | claimed |
| EP-0915898-B1 | CRYSTAL FORM I OF CLARITHROMYCIN | ABBOTT LAB (US) | 2003-12-03 | — | — | EP | claimed |
| US-5858986-A | CONVERTING ERYTHROMYCIN A INTO ITS 9-OXIME DERIVATIVE; PROTECTING 2' AND 4? HYDROXY GROUPS; METHYLATION; DEPROTECTING AND DEOXIMATING; TREATING WITH SOLVENT; ISOLATION; DRYING | ABBOTT LABORATORIES (US) | 1999-01-12 | — | — | US | claimed |
| EP-2956439-B1 | PROCESS FOR PREPARING ATAZANAVIR SULPHATE | CIPLA LTD (IN) | 2019-01-09 | — | — | EP | disclosed |
| CN-109071788-A | Aliphatic polycarbonate resin, next door material, substrate and its manufacturing method, the manufacturing method of circuit board and Wiring method | 住友精化株式会社 | 2018-12-21 | — | — | CN | disclosed |
| CN-108884372-A | Pyrolytic adhesive | 国立大学法人东京农工大学 | 2018-11-23 | — | — | CN | disclosed |
| CN-108884218-A | Next door is formed with aliphatic polycarbonate resin, next door material, substrate and its manufacturing method, the manufacturing method of circuit board and Wiring method | 住友精化株式会社 | 2018-11-23 | — | — | CN | disclosed |
| US-9890121-B2 | Process for preparing atazanavir sulphate | CIPLA LIMITED (IN) | 2018-02-13 | — | — | US | disclosed |
| US-20160002166-A1 | Process for Preparing Atazanavir Sulphate | CIPLA LIMITED (IN) | 2016-01-07 | — | — | US | disclosed |
| EP-2956439-A1 | PROCESS FOR PREPARING ATAZANAVIR SULPHATE | Cipla Limited (IN) | 2015-12-23 | — | — | EP | disclosed |
| EP-2138871-B1 | OPTICAL COMPENSATION LAYER, OPTICALLY COMPENSATING FILM, AND PROCESSES FOR PRODUCING THESE | TOSOH CORP (JP) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014125270-A1 | PROCESS FOR PREPARING ATAZANAVIR SULPHATE | CIPLA HOUSE (IN) | 2014-08-21 | — | — | WO | disclosed |
| EP-0915898-B1 | CRYSTAL FORM I OF CLARITHROMYCIN | ABBOTT LAB (US) | 2003-12-03 | — | — | EP | disclosed |
| US-5858986-A | CONVERTING ERYTHROMYCIN A INTO ITS 9-OXIME DERIVATIVE; PROTECTING 2' AND 4? HYDROXY GROUPS; METHYLATION; DEPROTECTING AND DEOXIMATING; TREATING WITH SOLVENT; ISOLATION; DRYING | ABBOTT LABORATORIES (US) | 1999-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002166-A1 | Process for Preparing Atazanavir Sulphate | SAMHD1, TPMT, ASH2L | TSHR 4428/4885HCAR2 4524/4885CHRM2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.